Generic Name and Formulations:
Eprosartan (as mesylate) 400mg, 600mg; tabs.
- FDA to Patients: Do Not Stop Taking ARBs
- SAFETY ALERT: FDA Reports No Increased Risk of Cancer with Angiotensin Receptor Blockers
- FDA conducts safety review of cancer risk with angiotensin receptor blockers (ARBs)
Indications for TEVETEN:
Monotherapy: not volume depleted: initially 600mg once daily. Usual range: 400–800mg/day given as a single dose or in two divided doses.
Angiotensin II receptor blocker.
Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy or monitor closely. Renal impairment: monitor for worsening renal function. Renal artery stenosis. Severe CHF. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes.
Viral infection, injury, fatigue, abdominal pain, hypertriglyceridemia, arthralgia, depression, urinary tract or upper respiratory tract infection, rhinitis, pharyngitis, coughing, hypotension, rhabdomyolysis (rare).
Hepatic. 98% protein bound.
- 400mg tablets (Qty:30)
- appx. price $111.00